Medicare Enrolled
Dr. Paul Dato, M.D.
Urology Physician · La Mesa, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Dato from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dato?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dato
Dr. Paul Dato is an urology physician in La Mesa, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Dato performed 28,522 Medicare services across 2,262 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dato received a total of $426,177 from 61 pharmaceutical and/or device companies across 1329 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dato is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 6% volume in CA
$426,177 industry payments
Medicare Practice Summary
Medicare Utilization ↗28,522
Medicare services
Top 6% in CA for urology physician
2,262
Unique beneficiaries
$70
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,426 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 16,800 | $18 | $75 |
| Injection, degarelix, 1 mg | 5,520 | $3 | $15 |
| Leuprolide injectable, camcevi, 1 mg | 966 | $64 | $99 |
| Additional chronic care management time, 60 minutes This service covers an additional 60 minutes of clinical staff time directed by a healthcare professional for managing two or more chronic conditions, billed per calendar month. |
905 | $60 | $336 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 535 | $134 | $716 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
491 | $98 | $600 |
| Chronic care management, additional 20 min/month This service covers an extra 20 minutes of clinical staff time directed by a healthcare professional for managing two or more chronic conditions each calendar month. |
442 | $40 | $240 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
326 | $51 | $300 |
| Additional 30 minutes of principal care management This service covers each additional 30 minutes of clinical staff time directed by a healthcare professional for managing a single high-risk disease, billed per calendar month. |
314 | $40 | $270 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
290 | $67 | $440 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
281 | $28 | $180 |
| Complex chronic care management, first 60 minutes This service involves clinical staff time directed by a healthcare professional to manage two or more chronic conditions over a calendar month. It covers the first 60 minutes of this coordinated care effort. |
244 | $112 | $640 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
240 | $11 | $80 |
| Principal care management for high-risk disease, first 30 minutes This service covers the initial 30 minutes of clinical staff time per calendar month to manage a single high-risk disease. It is directed by a healthcare professional. |
168 | $51 | $170 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
164 | $72 | $440 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
128 | $3 | $20 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
95 | $145 | $840 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
74 | $19 | $120 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
70 | $0 | $2 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
65 | $100 | $600 |
| Injection, tobramycin sulfate, up to 80 mg | 62 | $2 | $15 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
58 | $8 | $35 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
56 | $123 | $730 |
| Prostate gland biopsy A procedure to remove small samples of tissue from the prostate gland for laboratory examination. |
54 | $206 | $1,180 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
40 | $2 | $9 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
31 | $10 | $60 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
30 | $56 | $335 |
| Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | 30 | $42,060 | $99,664 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
16 | $40 | $280 |
| Manual urinalysis with microscopic examination A urine test performed manually without automated equipment. The sample is examined under a microscope to check for abnormalities. |
15 | $4 | $10 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
12 | $205 | $1,230 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.2% high complexity
81.0% medium
18.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$426,177
Total received (2018-2024)
Avg $60,882/year across 7 years
Top 1% in CA for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
61
Companies
1,329
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$393,334 (92.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$20,239 (4.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,605 (3.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$71,104
2023
$85,599
2022
$51,528
2021
$40,427
2020
$28,089
2019
$33,900
2018
$115,531
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$42,119
Astellas Pharma US Inc
$6,312
Telix Pharmaceuticals
$5,934
Bayer Healthcare Pharmaceuticals Inc.
$5,673
Dendreon Pharmaceuticals LLC
$4,843
PFIZER INC.
$3,870
Sumitomo Pharma America, Inc.
$425
Edap Technomed Inc
$372
Blue Earth Diagnostics Limited
$295
AstraZeneca Pharmaceuticals LP
$293
SUN PHARMACEUTICAL INDUSTRIES INC.
$204
ABBVIE INC.
$137
ACCORD HEALTHCARE, INC.
$110
Merck Sharp & Dohme LLC
$109
Myriad Genetic Laboratories, Inc.
$95
PROGENICS PHARMACEUTICALS, INC.
$80
Janssen Scientific Affairs, LLC
$77
Tempus AI, Inc
$59
IMMUNITYBIO, INC.
$42
Novartis Pharmaceuticals Corporation
$26
CIVCO Medical Instruments
$15
UROGEN PHARMA, INC.
$14
Top 3 companies account for 76.5% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$101,918
Dendreon Pharmaceuticals LLC
$64,175
Janssen Scientific Affairs, LLC
$59,858
Astellas Pharma US Inc
$56,187
PFIZER INC.
$39,606
Bayer Healthcare Pharmaceuticals Inc.
$35,645
Bayer HealthCare Pharmaceuticals Inc.
$24,497
Myovant Sciences Inc.
$19,492
Telix Pharmaceuticals
$5,995
Pfizer Inc.
$3,489
GENZYME CORPORATION
$2,826
Clinical Laserthermia Systems Americas Inc.
$1,159
Myriad Genetic Laboratories, Inc.
$997
AstraZeneca Pharmaceuticals LP
$937
Blue Earth Diagnostics Limited
$840
Amgen Inc.
$766
Sumitomo Pharma America, Inc.
$754
UroGen Pharma, Inc.
$650
Sun Pharmaceutical Industries Inc.
$615
EDAP TECHNOMED INC
$518
Merck Sharp & Dohme LLC
$467
AbbVie, Inc.
$389
Ferring Pharmaceuticals Inc.
$388
Edap Technomed Inc
$372
AbbVie Inc.
$317
SUN PHARMACEUTICAL INDUSTRIES INC.
$313
Foundation Medicine, Inc.
$296
ABBVIE INC.
$272
MEDIVATION FIELD SOLUTIONS LLC
$236
TOLMAR Pharmaceuticals, Inc.
$211
Progenics Pharmaceuticals, Inc.
$196
Merck Sharp & Dohme Corporation
$193
SANOFI-AVENTIS U.S. LLC
$167
Teleflex LLC
$133
ACCORD HEALTHCARE, INC.
$125
Photocure Inc
$118
Novartis Pharmaceuticals Corporation
$112
Antares Pharma, Inc.
$103
Avadel Specialty Pharmaceuticals, LLC
$101
PROGENICS PHARMACEUTICALS, INC.
$80
Verity Pharmaceuticals Inc.
$67
Tempus AI, Inc
$59
NeoTract Inc.
$53
IMMUNITYBIO, INC.
$42
Accord Healthcare, Inc.
$42
Rochester Medical Corporation
$42
180 Medical, Inc.
$42
Clovis Oncology, Inc.
$39
Tolmar, Inc.
$35
Palette Life Sciences, Inc.
$34
PALETTE LIFE SCIENCES, INC.
$26
Bard Access Systems, Inc.
$24
AngioDynamics, Inc.
$24
Agiliti Surgical, Inc.
$23
Boston Scientific Corporation
$22
Analogic Corporation
$21
Endo Pharmaceuticals Inc.
$18
CIVCO Medical Instruments
$15
Coloplast Corp
$14
UROGEN PHARMA, INC.
$14
SonaCare Medical, LLC
$8
Top 3 companies account for 53.0% of all-time payments
Associated products mentioned in payments ›
AKEEGA · ANKTIVA · AVEED · Axumin · BRACANALYSIS CDX · BRACAnalysis CDx · CAMCEVI · CHANTIX · CREON · CYSVIEW · ELIGARD · ERLEADA · EVENITY · Erleada · FIRMAGON · FOUNDATIONONE · GENTLECATH · ILLUCCIX · JELMYTO · JEVTANA · KEYTRUDA · LASER APPLICATOR NON-COOLED · LUPRON DEPOT · LYNPARZA · Lofric Origo · Lupron · Lupron Depot · MOBILE LASER UNIT · MYRBETRIQ · Myrbetriq · NANOKNIFE · NOCDURNA · Noctiva · Non-Covered · Nubeqa · ORGOVYX · OTREXUP · Odomzo · PLUVICTO · POSLUMA · PROLARIS · PROVENGE · PYLARIFY · Prolaris · Prolia · REZUM · Rubraca · SPEEDICATH · SonaBlate · TALZENNA · Trelstar · UroLift · UroLift System · XGEVA · XTANDI · XYOSTED · Xofigo · Xtandi · YONSA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in urology physician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for urology physician in CA.
Geographic Context
Urology physicians within 10 mi
131
Per 100K population
4.0
County median income
$102,285
Nearest hospital
GROSSMONT HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Dato is a mixed practice specialist, with above-average Medicare volume (top 6% in CA), with speaking/promotional industry engagement in the top 1% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Dato experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Dato performed 16,800 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dato receive payments from pharmaceutical companies?
Yes. Dr. Dato received a total of $426,177 from 61 companies across 1,329 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dato's costs compare to other urology physicians in La Mesa?
Dr. Dato's average Medicare payment per service is $70. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dato) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in La Mesa
Browse urology physicians in La Mesa ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in CA
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in CA
Which CA urology physicians receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Dendreon Pharmaceuticals LLC Payments to Doctors
See all physicians who received payments from Dendreon Pharmaceuticals LLC.
By company
Janssen Scientific Affairs, LLC Payments to Doctors
See all physicians who received payments from Janssen Scientific Affairs, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology